Health
Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma – News-Medical.Net
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency…
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference. NAVIGATOR (NCT03347279) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial.
Tezepelumab offers new therapeutic opportunities for patients…
-
Noosa News19 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News22 hours agoFrom Dreamy Dining Rooms to Moody Basement Bars, Nearly 200 Venues Have Been Shortlisted for the 2025 Australian Interior Design Awards
-
Noosa News19 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General18 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off